Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
Identifieur interne : 003B70 ( Main/Exploration ); précédent : 003B69; suivant : 003B71Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
Auteurs : Hila Haskelberg [Argentine] ; Patrick W G. Mallon ; Jennifer Hoy ; Janaki Amin ; Cecilia Moore ; Praphan Phanuphak ; Samuel Ferret ; Waldo H. Belloso ; Mark A. Boyd ; David A. Cooper ; Sean EmerySource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2014.
Descripteurs français
- KwdFr :
- Absorptiométrie photonique, Adulte, Agents antiVIH (administration et posologie), Agents antiVIH (effets indésirables), Densité osseuse (), Femelle, Humains, Lopinavir (administration et posologie), Lopinavir (effets indésirables), Mâle, Os coxal (imagerie diagnostique), Pyrrolidones (administration et posologie), Pyrrolidones (effets indésirables), Rachis (imagerie diagnostique), Raltégravir de potassium, Ritonavir (administration et posologie), Ritonavir (effets indésirables), Études longitudinales.
- MESH :
- administration et posologie : Agents antiVIH, Lopinavir, Pyrrolidones, Ritonavir.
- effets indésirables : Agents antiVIH, Lopinavir, Pyrrolidones, Ritonavir.
- imagerie diagnostique : Os coxal, Rachis.
- Absorptiométrie photonique, Adulte, Densité osseuse, Femelle, Humains, Mâle, Raltégravir de potassium, Études longitudinales.
English descriptors
- KwdEn :
- Absorptiometry, Photon, Adult, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (adverse effects), Bone Density (drug effects), Female, Humans, Longitudinal Studies, Lopinavir (administration & dosage), Lopinavir (adverse effects), Male, Pelvic Bones (diagnostic imaging), Pyrrolidinones (administration & dosage), Pyrrolidinones (adverse effects), Raltegravir Potassium, Ritonavir (administration & dosage), Ritonavir (adverse effects), Spine (diagnostic imaging).
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Lopinavir, Pyrrolidinones, Ritonavir.
- chemical , adverse effects : Anti-HIV Agents, Lopinavir, Pyrrolidinones, Ritonavir.
- diagnostic imaging : Pelvic Bones, Spine.
- drug effects : Bone Density.
- Absorptiometry, Photon, Adult, Female, Humans, Longitudinal Studies, Male, Raltegravir Potassium.
Abstract
To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs] + LPV/r second-line therapy.
DOI: 10.1097/QAI.0000000000000288
PubMed: 25072617
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003438
- to stream PubMed, to step Curation: 003325
- to stream PubMed, to step Checkpoint: 003325
- to stream Ncbi, to step Merge: 001C70
- to stream Ncbi, to step Curation: 001C70
- to stream Ncbi, to step Checkpoint: 001C70
- to stream Main, to step Merge: 003C18
- to stream Main, to step Curation: 003B70
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.</title><author><name sortKey="Haskelberg, Hila" sort="Haskelberg, Hila" uniqKey="Haskelberg H" first="Hila" last="Haskelberg">Hila Haskelberg</name><affiliation wicri:level="1"><nlm:affiliation>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name></author><author><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name></author><author><name sortKey="Moore, Cecilia" sort="Moore, Cecilia" uniqKey="Moore C" first="Cecilia" last="Moore">Cecilia Moore</name></author><author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name></author><author><name sortKey="Ferret, Samuel" sort="Ferret, Samuel" uniqKey="Ferret S" first="Samuel" last="Ferret">Samuel Ferret</name></author><author><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25072617</idno><idno type="pmid">25072617</idno><idno type="doi">10.1097/QAI.0000000000000288</idno><idno type="wicri:Area/PubMed/Corpus">003438</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003438</idno><idno type="wicri:Area/PubMed/Curation">003325</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003325</idno><idno type="wicri:Area/PubMed/Checkpoint">003325</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003325</idno><idno type="wicri:Area/Ncbi/Merge">001C70</idno><idno type="wicri:Area/Ncbi/Curation">001C70</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C70</idno><idno type="wicri:Area/Main/Merge">003C18</idno><idno type="wicri:Area/Main/Curation">003B70</idno><idno type="wicri:Area/Main/Exploration">003B70</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.</title><author><name sortKey="Haskelberg, Hila" sort="Haskelberg, Hila" uniqKey="Haskelberg H" first="Hila" last="Haskelberg">Hila Haskelberg</name><affiliation wicri:level="1"><nlm:affiliation>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name></author><author><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name></author><author><name sortKey="Moore, Cecilia" sort="Moore, Cecilia" uniqKey="Moore C" first="Cecilia" last="Moore">Cecilia Moore</name></author><author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name></author><author><name sortKey="Ferret, Samuel" sort="Ferret, Samuel" uniqKey="Ferret S" first="Samuel" last="Ferret">Samuel Ferret</name></author><author><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (adverse effects)</term><term>Bone Density (drug effects)</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Lopinavir (administration & dosage)</term><term>Lopinavir (adverse effects)</term><term>Male</term><term>Pelvic Bones (diagnostic imaging)</term><term>Pyrrolidinones (administration & dosage)</term><term>Pyrrolidinones (adverse effects)</term><term>Raltegravir Potassium</term><term>Ritonavir (administration & dosage)</term><term>Ritonavir (adverse effects)</term><term>Spine (diagnostic imaging)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Absorptiométrie photonique</term><term>Adulte</term><term>Agents antiVIH (administration et posologie)</term><term>Agents antiVIH (effets indésirables)</term><term>Densité osseuse ()</term><term>Femelle</term><term>Humains</term><term>Lopinavir (administration et posologie)</term><term>Lopinavir (effets indésirables)</term><term>Mâle</term><term>Os coxal (imagerie diagnostique)</term><term>Pyrrolidones (administration et posologie)</term><term>Pyrrolidones (effets indésirables)</term><term>Rachis (imagerie diagnostique)</term><term>Raltégravir de potassium</term><term>Ritonavir (administration et posologie)</term><term>Ritonavir (effets indésirables)</term><term>Études longitudinales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Lopinavir</term><term>Pyrrolidinones</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term><term>Lopinavir</term><term>Pyrrolidinones</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Lopinavir</term><term>Pyrrolidones</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Pelvic Bones</term><term>Spine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Lopinavir</term><term>Pyrrolidones</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Os coxal</term><term>Rachis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Raltegravir Potassium</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Absorptiométrie photonique</term><term>Adulte</term><term>Densité osseuse</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Raltégravir de potassium</term><term>Études longitudinales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs] + LPV/r second-line therapy.</div></front></TEI><affiliations><list><country><li>Argentine</li></country></list><tree><noCountry><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><name sortKey="Ferret, Samuel" sort="Ferret, Samuel" uniqKey="Ferret S" first="Samuel" last="Ferret">Samuel Ferret</name><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name><name sortKey="Moore, Cecilia" sort="Moore, Cecilia" uniqKey="Moore C" first="Cecilia" last="Moore">Cecilia Moore</name><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name></noCountry><country name="Argentine"><noRegion><name sortKey="Haskelberg, Hila" sort="Haskelberg, Hila" uniqKey="Haskelberg H" first="Hila" last="Haskelberg">Hila Haskelberg</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25072617
|texte= Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25072617" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |